Fig. 3
NIR-II
fluorophores CH1055 and imaging in vivo. (a) Chemical structure of CH1055-PEG. (b) The absorbance and
fluorescent emission of CH1055PEG (808 nm excitation). (c) Brain vasculature imaging through the scalp and skull in mice using either ICG and CH1055-PEG. (d) PEGylated CH1055 shows
90% renal clearance in the
first 24 h post-injection. (e) A simplified reaction schematic illustrating the synthesis of the CH1055-affibody. (f) NIR-II
fluorescent
images 6 h post-injection of CH1055 conjugated to an anti-EGFR affibody as well as of a blocking dose to demonstrate molecular selectivity. (a–f) Reprinted
(adapted) with permission from Ref. [8], Copyright 2015, Nature Publishing Group
Advancements of Second Near-Infrared Biological Window Fluorophores:. . .
87
NIR-II
fluorophores CH1055 and imaging in vivo. (a) Chemical structure of CH1055-PEG. (b) The absorbance and
fluorescent emission of CH1055PEG (808 nm excitation). (c) Brain vasculature imaging through the scalp and skull in mice using either ICG and CH1055-PEG. (d) PEGylated CH1055 shows
90% renal clearance in the
first 24 h post-injection. (e) A simplified reaction schematic illustrating the synthesis of the CH1055-affibody. (f) NIR-II
fluorescent
images 6 h post-injection of CH1055 conjugated to an anti-EGFR affibody as well as of a blocking dose to demonstrate molecular selectivity. (a–f) Reprinted
(adapted) with permission from Ref. [8], Copyright 2015, Nature Publishing Group
Advancements of Second Near-Infrared Biological Window Fluorophores:. . .
87